美托洛尔联合缬沙坦对高血压左室肥厚及左室舒张功能的影响

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (550 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective Effect of metoprolol combined with valsartan for treatment of hypertensive patients with left ventricular hypertrophy and left ventricular diastolic function was observed. Methods In this study, we recruited 180 patients diagnosed as having hypertension and left ventricular hypertrophy (LVH) by echocardiographic examination and randomly divided them into three groups, A, B and C. The treatment of the patients in group A was given metoprolol and valsartan; the group B was given valsartan; the group C was given metoprolol; all treatment courses were one year. Echocardiography, 24-hour ambulatory blood pressure, and electrocardiogram were checked, and left ventricular muscle weight and left ventricular mass index were measured. The effects and group differences after and before treatment were compared. Results After treatment, in all patients, blood pressure was well-controlled, left ventricular hypertrophy, left ventricular diastolic function were improved (P<0.01). But group A obtained better efficacy than group B and group C (P<0.01), especially the left ventricular mass index in group A dropped clearly from (136.8±7.3)g/m² down to (127.7±4.6)g/m² (P<0.01), the left ventricular diastolic function improved. Conclusions Metoprolol in combination with valsartan to treat hypertension can reduce blood pressure, and left ventricular hypertrophy, and improve left ventricular diastolic function.

Key words： metoprolol valsartan hypertension ventricular hypertrophy left ventricular diastolic function

Received: 28 July 2015

ZTFLH:

R544.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HAN Yanhua
	YANG Chunmei
	SONG Zhonghai
	LI Yubin
	XU Bin
	and LI Qiuying

Cite this article:

HAN Yanhua,YANG Chunmei,SONG Zhonghai等. Effect of metoprolol combined with valsartan on hypertensive left ventricular hypertrophy and left ventricular diastolic function[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2015, 26(12): 1234-1236.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2015/V26/I12/1234

[2]	赵水平,胡大一.高血压.心血管病诊疗指南解读[M].3版.北京:人民卫生出版社,2008: 48-79.
[3]	彭钰,吴禹池,周敏, 等.老年维持性血液透析患者心脏结构功能特点及危险因素[J].中国老年学杂志,2012,32(7):2708-2709.
[1]	邹云增,李磊. AT1活化性机制及其阻断药作用研究的新观点:心血管病诊治新进展2011-2012[M]. 北京:人民军医出版社,2012:22-27.
[4]	Roy G C, Sutradhar S R, Barna U K, et al. Cardiovascular complications of chronic renal failure-an updated review [J]. Mymensingh Med J,2012,21(3):573-579.
[5]	孙宁玲,王鸿懿,陈源源,等. ERK表达及活化在自发性高血压大鼠心肌肥厚中作用的研究[J].高血压杂志,2002, 10(4): 352-355。
[6]	李莹,徐克雷.高血压治疗的研究进展与展望[J]. 实用心脑肺血管病杂志,2013,21(8):1-4.
[2]	赵水平,胡大一.高血压.心血管病诊疗指南解读[M].3版.北京:人民卫生出版社,2008: 48-79.
[3]	彭钰,吴禹池,周敏, 等.老年维持性血液透析患者心脏结构功能特点及危险因素[J].中国老年学杂志,2012,32(7):2708-2709.
[7]	柯元南.高血压的联合治疗[M]//高润霖,胡大一.心血管病学.北京: 中华医学电子音像出版社,2008: 20-24.
[4]	Roy G C, Sutradhar S R, Barna U K, et al. Cardiovascular complications of chronic renal failure-an updated review [J]. Mymensingh Med J,2012,21(3):573-579.
[5]	孙宁玲,王鸿懿,陈源源,等. ERK表达及活化在自发性高血压大鼠心肌肥厚中作用的研究[J].高血压杂志,2002, 10(4): 352-355。
[8]	王吉耀,廖二元,胡品津.内科学(7年、8年制)[M].北京: 人民卫生出版社,2005: 251-253.
[9]	陈江波.厄贝沙坦联合美托洛尔治疗中青年高血压病的临床观察[J]. 中西医结合心脑血管病杂志,2014,12(3): 292-293.
[10]	陈小莉. 厄贝沙坦联合美托洛尔治疗老年高血压病的临床分析[J]. 中国药物经济学,2014,9(8): 51-52.
[6]	李莹,徐克雷.高血压治疗的研究进展与展望[J]. 实用心脑肺血管病杂志,2013,21(8):1-4.
[7]	柯元南.高血压的联合治疗[M]//高润霖,胡大一.心血管病学.北京: 中华医学电子音像出版社,2008: 20-24.
[8]	王吉耀,廖二元,胡品津.内科学(7年、8年制)[M].北京: 人民卫生出版社,2005: 251-253.
[9]	陈江波.厄贝沙坦联合美托洛尔治疗中青年高血压病的临床观察[J]. 中西医结合心脑血管病杂志,2014,12(3): 292-293.
[10]	陈小莉. 厄贝沙坦联合美托洛尔治疗老年高血压病的临床分析[J]. 中国药物经济学,2014,9(8): 51-52.